ArticleNPJ microgravity2025
BMP9 attenuates microgravity-related disuse osteoporosis by modulating TGFβ and BMP signaling.
Article in NPJ microgravity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Disuse osteoporosis, caused by mechanical unloading, is linked to dysregulated TGFβ and BMP signaling. This study explores their roles and evaluates BMP9 as a potential therapy. A hindlimb unloading (HLU) mouse model was used to assess bone changes and signaling alterations. In vitro, a Rotary Cell Culture System (RCCS) with 3D printing simulated microgravity. BMP9 was overexpressed in bone marrow stromal cells (BMSCs) and osteocytes treated with TGFβ1. HLU mice showed reduced bone density, microstructural integrity, and dysregulated signaling (increased p-Smad2/3, decreased p-Smad1/5/8). BMP9 overexpression restored osteogenic differentiation in vitro and improved bone properties in vivo. However, RCCS failed to replicate osteogenic inhibition, likely due to shear stress. Despite challenges, BMP9 shows promise for treating disuse osteoporosis. Future research will refine vector specificity and reduce immunogenicity for clinical application.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.